Find News

Filter articles

Applied Filters

Showing 71 to 80 of 909 results

Judge approves $120m Momenta and Sandoz settlement

US06-01-2020Rory O'Neill

A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Generics makers appeal pay-for-delay ban to Ninth Circuit

US03-01-2020Rory O'Neill

A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.

Adamas settles Gocovri clash with Sandoz

US03-01-2020Sarah Morgan

California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

Eli Lilly secures Alimta patent win over Apotex

US02-01-2020Rory O'Neill

Eli Lilly has won a victory in a cancer drug dispute after a federal judge ruled that Canadian pharmaceutical company Apotex’s new drug application infringed the company’s patent.

Sandoz and Momenta to pay $120m to end antitrust suit

US24-12-2019Sarah Morgan

Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Bausch Health resolves patent litigation with Glenmark

Canada, US23-12-2019Sarah Morgan

Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.

Supermarket chain settles pay-for-delay suit over birth control pill

19-12-2019Rory O'Neill

Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.

Momenta to pay $35m to end enoxaparin class-action suit

12-12-2019Rory O'Neill

Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

US senators question ‘national security risks’ posed by Chinese drugs

US11-12-2019Saman Javed

US senators have requested information regarding the national security risks posed by the role of foreign manufacturing, specifically in China, in the US pharmaceutical products supply chain.

McDonald Hopkins adds new recruit in Chicago

US11-12-2019Rory O'Neill

McDonald Hopkins has added Erin Conway as counsel to its IP litigation department in Chicago.

Showing 71 to 80 of 909 results